Xenetic Biosciences (XBIO) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares.
View XBIO analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12 month price targets for Xenetic Biosciences' stock. Their XBIO share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,153.9% from the stock's current price.
View analysts price targets for XBIO or view top-rated stocks among Wall Street analysts.

Xenetic Biosciences' stock was trading at $2.8510 at the beginning of the year. Since then, XBIO stock has increased by 11.9% and is now trading at $3.19.
View the best growth stocks for 2023 here.

Xenetic Biosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 800 shares, a decrease of 77.8% from the April 30th total of 3,600 shares. Based on an average daily trading volume, of 19,900 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company's shares are sold short.
View Xenetic Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our XBIO earnings forecast.

Xenetic Biosciences Inc (NASDAQ:XBIO) released its earnings results on Thursday, March, 23rd. The company reported ($1.00) earnings per share for the quarter. The business earned $0.49 million during the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 41.39% and a negative net margin of 302.29%.

Xenetic Biosciences's stock reverse split before market open on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.66%) and Susquehanna International Group LLP (0.51%).

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XBIO stock can currently be purchased for approximately $3.19.

Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $4.85 million and generates $1.71 million in revenue each year. The company earns $-6,550,000.00 in net income (profit) each year or ($4.10) on an earnings per share basis.

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com.